0000899866-20-000018.txt : 20200303 0000899866-20-000018.hdr.sgml : 20200303 20200303181658 ACCESSION NUMBER: 0000899866-20-000018 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Franchini Indrani Lall CENTRAL INDEX KEY: 0001708764 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 20684508 MAIL ADDRESS: STREET 1: C/O ALEXION PHARMACEUTICALS, INC STREET 2: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 4 1 wf-form4_158327740132826.xml FORM 4 X0306 4 2020-02-28 0 0000899866 ALEXION PHARMACEUTICALS, INC. ALXN 0001708764 Franchini Indrani Lall C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210 0 1 0 0 EVP, Chief Compliance Officer Common Stock, par value $.0001 per share 2020-02-28 4 A 0 9520 0 A 37741 D Common Stock, par value $.0001 per share 2020-03-02 4 F 0 1267 90.54 D 36474 D Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Douglas J. Barry, Attorney-in-Fact for Indrani L. Franchini 2020-03-03